ArticleTranslational neurodegeneration2012
Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau.
Article in Translational neurodegeneration, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 101 citations in OpenAlex.
- Rather a versatile multi-tool than a sword: an integral role of the plasminogen system in health and disease.Frontiers in immunology · 2026Review
- Review on Molecular Targeting, Pharmacological Action, and Advanced Biopharmaceutical Aspects for the Management of Alzheimer's Disease.Current pharmaceutical design · 2026Review
- In vitro and in silico neuroprotective evaluation of new biotransformation metabolites of (-)-α-bisabolol.Scientific reports · 2025Article
- Neuroprotective Effect of Chlorogenic Acid in an Animal Model of Sporadic Alzheimer's Disease Induced by Streptozotocin.Molecular neurobiology · 2025Article
- Translation from Preclinical Research to Clinical Trials: Transdermal Drug Delivery for Neurodegenerative and Mental Disorders.Pharmaceutical research · 2024Review
- Review
- Review
- Pharmacological implications of ipriflavone against environmental metal-induced neurodegeneration and dementia in rats.Environmental science and pollution research international · 2021Article
- Pharmacological inhibition of asparaginyl endopeptidase by δ-secretase inhibitor 11 mitigates Alzheimer's disease-related pathologies in a senescence-accelerated mouse model.Translational neurodegeneration · 2021Article
- Borrelidin from Saltern-Derived HalophilicJournal of Alzheimer's disease reports · 2021Article
- Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease.International journal of molecular sciences · 2020Review
- Effects of Co-Administration of Icariin andNeuropsychiatric disease and treatment · 2020Article
- Peroxisome Proliferator-activated Receptor (PPAR)-γ Modifies Aβ Neurotoxin-induced Electrophysiological Alterations in Rat Primary Cultured Hippocampal Neurons.Iranian journal of pharmaceutical research : IJPR · 2019Article
- Rutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders.Oxidative medicine and cellular longevity · 2018Review
- A Brief Review on the Neuroprotective Mechanisms of Vitexin.BioMed research international · 2018Review
- Nec-1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in APP/PS1 mice.EMBO molecular medicine · 2017Article
- Mathematical model on Alzheimer's disease.BMC systems biology · 2016Article
- Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.BMC neurology · 2016Article
- Pharmacology and Clinical Drug Candidates in Redox Medicine.Antioxidants & redox signaling · 2015Review
- The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease.Future science OA · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that impairs mainly the memory and cognitive function in elderly. Extracellular beta amyloid deposition and intracellular tau hyperphosphorylation are the two pathological events that are thought to cause neuronal dysfunction in AD. Since the detailed mechanisms that underlie the pathogenesis of AD are still not clear, the current treatments are those drugs that can alleviate the symptoms of AD patients. Recent studies have indicated that these symptom-reliving drugs also have the ability of regulating amyloid precursor protein processing and tau phosphorylation. Thus the pharmacological mechanism of these drugs may be too simply-evaluated. This review summarizes the current status of AD therapy and some potential preclinical considerations that target beta amyloid and tau protein are also discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.